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Abstract. The effect of Nucleinat on bronchial hyper-
responsiveness, the parameters of the phagocytic activity 
and phagocytic index of neutrophils their oxygen-
dependent metabolism and the blood content of nitric oxide 
metabolites in 98 school age children with bronchial asthma 
has been studied by means of a double-blind placebo-
controlled method. Two clinical groups were formed with 
the help of the table of accidental numbers. The first clini-
cal group included 47 children who took Nucleinat in a 
dose of 0,25 g per diem during 21 days in a complex of 
base-line theraphy. The second clinical group was formed 
of 51 children who took placebo according to the same 
regimen. It has been shown that thanks to the use of Nu-
cleinat a reduction of bronchial hypersensitivity and optimi-
zation of disease control have been achieved, which was 
indirectly evidenced by an increased risk of detecting mod-
erate bronchial responsiveness to histamine (OR = 3,6; 95% 
CІ: 1,3-9,3) and a decrease of the phagocytic activity of 
neutrophils (OR=1,9 with 95% CI (0,9-4,4)). 
Key words: children, bronchial asthma, bronchial 
hyperresponsiveness, immunity, Nucleinat. 
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Introduction. Changes of the immune response 
underlie bronchial asthma (BA). They are the causes 
of the organism’s sensibilization, the development of 
bronchial allergic (immunologic) inflammation [5] 
and hyperresponsiveness [7]. Thanks to these inflam-
matory changes it is very important to use anti-
inflammatory drugs for children with bronchial 
asthma [11]. But, when we use basic therapy this 
child’s pathology, sometimes, it is impossible to at-
tain full control of the diseases [6]. The insufficient 
effectiveness of the inhalation of glucocorticosteroid 
(iGCS) [3] substantiates the use of new medications 
(for example Nucleinat) which can improve BA.  
Since Nucleinat possesses immunomodulating 
and antiinflammatory effects [9], it may be suggested 
that its use in combined basic therapy in children 
with bronchial asthma would be accompanied with 
the positive dynamics of bronchial hyperresponsive-
ness, the phagocytic activity and the phagocytic in-
dex of neutrophils, oxygen-dependent metabolism of 
neutrophilic granulocytes and the blood content of 
oxygen. 
The object of the study: To estimate the role of 
Nucleinat in the complex of control therapy of chil-
dren’s BA and its effects on bronchial hypersensitiv-
ity, the parameters of the phagocytic activity and the 
phagocytic index of neutrophils, oxygen-dependent 
metabolism of neutrophilic granulocytes and the 
blood content of nitric oxide (NO). 
Material and Methods: Altogether, 98 school-
age children with bronchial asthma during the period 
of remission were subjected to a complex examina-
tion. The examinations were performed by means of 
a double blind, randomized, placebo controlled 
method. Using the table of random numbers, all the 
patients were divided into two clinical groups. The 
first (I) group consisted of 47 patients, who were 
administered Nucleinat in a dose of 0.25 g/day for 21 
days as an addition to combined basic therapy. The 
second (II) group consisted of 51 patients, who, in-
stead of Nucleinat were administered placebo. The 
groups did not differ significantly by age, the dura-
tion of the disease, the levels of bronchial asthma 
control or the type of anti-inflammatory therapy. 
The first clinical group consisted of 32 boys 
(68,0 %) and 15 girls (31,9 %). The second clinical 
group consisted of 31 boys (60,8%, Pφ>0,05) and 20 
girls (39,2%, Pφ>0,05).  
The average child’s age was 11,7±0,5 years in 
the basic groups and 12,3±0,4 years (P>0,05) in the 
control group.  
According to the classifications of BA, which is 
in the GINA-2006, there were 5 children (10,6±4,5)% 
with controlled asthma in the first group and 9 patients 
(17,6±5,3)% in the second one (P>0,05), 24 children 
(51,1±7,1)% with partly controlled asthma of group I 
and 32 (62,7±6,8)% sick children of group II (P>0,05). 
Uncontrolled bronchial asthma was observed in 18 
children (38,3±7,1)% in the first group and in 10 pa-
tients (19,6±5,5)% in the second one (P<0,05). 
In addition to the generally accepted clinical 
examinations, the determination of respiratory tract 
hyperresponsiveness was performed with the use of a 
portable calibrating spirograph MicroLab (Micro 
Medical). Bronchial hypersensitivity was estimated 
by the findings of an inducing dose of histamine, 
which resulted in a 20% reduction of FEV1 
(PC20H), and a cumulative dose (PD20Н) with the 
use of a histamine serial dilution [12]. Bronchial 
reactivity was determined by means of the bronchial 
lability index (BLI). A response of the respiratory 
tracts to a dosed physical exercise (5-min running 
with a submaximal heart rate) as the bronchospasm 
index (BSI) and following the inhalation of a beta2-
agonist (salbutamol) as the bronchodilation index 
(BDI) [1]. At the same time, a blood immunological 
examination of the IInd-IIId levels was performed. In 
addition to an evaluation of the phagocytic activity 
(PA, percent) and the phagocytic index (PI, arbitrary 
units) of blood neutrophils, oxygen-dependent me-
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tabolism of neutrophilic granulocytes by the parame-
ters of both spontaneous and stimulated NBT-test, 
expressed in the form of a relative content (percent) 
of pharmasan-positive blood neutrophils (V.V. Kli-
mov et al., 1988) was carried out. A determination of 
blood nitric oxide was also performed (N.L. Yem-
chenko et al., 1994).  
Besides, the risk of the realisation of an event in 
the first group of children to the patients from the 
control group (OR with its CI) was calculated. 
Results and Discussion. Following the therapy 
carried out in both groups, a reduction in bronchial 
hypersensitivity was revealed in the form of an ele-
vated inducing and cumulative doses of histamine. 
However, significant elevations in PC20Н and PD20H 
were only noted in the patients of the first group, while 
a trend towards elevations of these parameters was 
noted in the second group patients (Tabl. 1). 
The results obtained can be explained by a reduc-
tion of the inflammatory component of bronchial hy-
persensitivity as a result of the therapy instituted [8]. 
The risk of a reduction of bronchial hypersensi-
tivity in the patients of the first clinical group was 
higher relative to the children, receiving placebo 
(OR=3,6; 95 % CІ: 1,3-9,3). 
Following the therapy, spirographic tests with a 
dosed physical exercise and with the inhalation of a 
beta2-agonist showed a trend towards elevations of 
the bronchial lability index in the patients of both 
groups (Tabl. 2). 
Therefore, a clear trend towards a rise in bron-
chial sensitivity to beta2-agonist inhalation, but with 
unchanged bronchospasm as the respiratory tract 
response to physical exercise was noted in the chil-
dren receiving Nucleinat. The trend towards en-
hanced sensitivity of the respiratory tracts to a bron-
chodilatator, but with the same bronchospasm fol-
lowing a dosed physical exercise in the Nucleinat 
recipients could be explained by a reduction of the 
inflammatory component, but with the preserved 
hereditary component of bronchial reactivity [4]. 
At the same time, following the therapy in the 
patients of both clinical groups changes in the oxida-
tion-reduction processes in the blood neutrophilic 
granulocytes were noted and which were confirmed 
by the NBT-test findings in both spontaneous and 
stimulated versions. Thus, significant reductions in 
the oxygen-dependent bactericidal action of neutro-
phils were revealed in the children, who received Nu-
cleinat, but only those based on the parameters of the 
spontaneous NBT-test in the second group patients. 
An estimation of the relative content of blood neutro-
phils stimulated with pyrogenal showed a trend to-
wards their reductions in the patients of both clinical 
groups. An estimation of the functional activity pa-
rameters of the phagocytic immunity link showed that 
Nucleinat in the complex of the basic therapy of chil-
dren’s BA didn’t change substantially the phagocytic 
index and phagocytic activity (Tabl. 3). 
Significant reductions in the percentage of 
pharmasan-positive neutrophils in patients of the first 
clinical group indicate a plausible reduction of the 
body’s chronic inflammatory process [12].  
It is necessary to note, that the probability of a 
decrease of the phagocytic activity in the patients of 
the 1st-clinical group relative to the children, receiv-
ing placebo was increased (OR=1,9 with 95 % CI 
(0,9-4,4)). 
Following the therapy performed, a significant 
elevation of the blood nitric oxide content was noted 
in the first clinical group patients who received Nu-
cleinat (Tabl. 4). 
The significant elevated blood nitric oxide con-
tent in the first clinical group patients, who received 
Table 1 
Parameters of respiratory tract hypersensitivity in patients of both clinical groups 
Group 
 Therapy 
PC20H (mg/ml) PD20H (mg) 
І group (n=47) ІІ group (n=51) І group (n=47) ІІ group (n=51) 
Prior to the therapy 1,3±0,2 1,7±0,3 0,29±0,05 0,37±0,06 
Following the therapy 2,8±0,5 2,2±0,4 0,6±0,1 0,48±0,1 
Р Р<0,05 Р>0,05 Р<0,05 Р>0,05 
Table 2 
Parameters of the respiratory tract hyperreactivity in patients  
of both clinical groups 
Group 
Therapy 








(n=33) І group (n=32) 
ІІ group 
(n=33) 
Prior to the  
therapy 23,4±2,3 22,4±2,2 9,9±1,4 11,3±1,6 12,4±1,8 11,1±1,2 
Following the 
therapy 24,6±2,5 24,8±3,3 11,7±1,6 10,8±1,2 13,04±1,6 14,0±2,7 
Р P>0,05 P>0,05 P>0,05 P>0,05 P>0,05 P>0,05 
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Table 3 
Functional activity parameters of blood neutrophils in patients  
of both clinical groups 
Group 






















(n=47) 36,2±2,5 28,0±2,0* 51,3±2,6 45,8±2,6 80,1±1,7 78,3±2,3 9,1±0,6 7,8±2,3 
ІІ group (n=51) 31,4±1,8 32,1±2,1 46,4±2,4 43,3±2,2 80,9±1,3 83,9±1,3 9,1±0,6 9,9±0,5 
Note. *P<0,05 
Table 4 
Blood nitric oxide content in the patients of both clinical groups 
Group of patients 
Therapy 
NO, mcmol/L 
І group (n=32) ІІ group (n=33) 
Prior to the therapy 19,6±0,7 20,1±1,5 
Following the therapy 25,9±2,9 18,6±0,4 
Р P<0,05 P>0,05 
Nucleinat, could be explained by a plausible reduc-
tion in the manifestations of chronic hypoxia, which 
is inherent to this disease [6].  
Therefore, the use of Nucleinat in combined 
therapy for bronchial asthma ensures a significant 
reduction of the inflammatory process in children, 
manifested by lowered bronchial hyperresponsive-
ness, lowered oxygen-dependent bactericidal activity 
of neutrophils and reduced signs of chronic hypoxia 
(an elevated blood content of nitric oxide). 
Conclusions 
1. The use of Nucleinat in combined therapy for 
bronchial asthma in children ensures a significant re-
duction in bronchial hyperresponsiveness. The risk of a 
reduction of bronchial hypersensitivity in the first clini-
cal group of patients was higher relative to the chil-
dren, receiving placebo (OR = 3,6; 95% CІ: 1,3-9,3). 
2. Following the use of Nucleinat, a clear trend 
was noted towards an elevated bronchodilation after 
beta2-agonist inhalation. 
3. The use of Nucleinat in combined therapy for 
bronchial asthma was accompanied with significant 
reductions in the parameters of oxygen-dependent 
bactericidal action of blood neutrophilic granulo-
cytes. The probability of a decrease of the phago-
cytic activity in the Ist clinical group patients relative 
to the children receiving placebo, was increased 
(OR=1,9 with 95% CI (0,9-4,4)). 
4. Following the use of Nucleinat, a clear trend 
was noted towards an elevated level of the blood 
nitric oxide. 
Perspectives of future investigations in this 
direction are to estimate the effect of Nucleinat in 
the complex of control therapy of children’s BA on 
the rate of the clinical signs. 
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КАКАЯ РОЛЬ НУКЛЕИНАТА В КОМПЛЕКСЕ КОНТРОЛИРУЮЩЕЙ ТЕРАПИИ  
БРОНХИАЛЬНОЙ АСТМЫ У ШКОЛЬНИКОВ? ДВАЖДЫ СЛЕПОЕ ПЛАЦЕБО–  
КОНТРОЛИРОВАННОЕ ИССЛЕДОВАНИЕ 
Л.О.Безруков, О.К.Колоскова, У.И.Марусик 
Резюме. Дважды слепым плацебо– контролированным методом проведено исследование влияния Нуклеината 
на гипервосприимчивость дыхательных путей, показатели фагоцитарной активности и фагоцитарного числа нейт-
рофилов, их кислородозависимого метаболизма и концентрации метаболитов оксида азота в крови в комплексном 
лечении бронхиальной астмы у 98 школьников. С помощью таблицы случайных чисел было сформировано две 
клинические группы. В первую клиническую группу вошли 47 больных, которые в комплексе базисной терапии 
принимали Нуклеинат в дозе 0,25 г в сутки в течение 21 дня. Вторую группу сформировали 51 школьник, которые 
получали плацебо. Показано, что благодаря использованию Нуклеината достигнуто снижение гипервосприимчиво-
сти дыхательных путей, а также оптимизации контроля этого заболевания, на что косвенно указывал прирост риска 
выявления умеренной восприимчивости бронхов к гистамину (СШ=3,6; 95 % ДИ: 1,3-9,3) и снижение фагоцитар-
ной активности нейтрофилов (СШ=1,9 з 95 % ДИ (0,9-4,4)). 
Ключевые слова: дети, бронхиальная астма, гипервосприимчивость бронхов, иммунитет, Нуклеинат. 
ЯКА РОЛЬ НУКЛЕЇНАТУ В КОМПЛЕКСІ КОНТРОЛЬОВАНОЇ ТЕРАПІЇ  
БРОНХІАЛЬНОЇ АСТМИ У ШКОЛЯРІВ? ДВІЧІ СЛІПИЙ  
ПЛАЦЕБО-КОНТРОЛЬОВАНИЙ МЕТОД 
Л.О.Безруков, О.К.Колоскова, У.І.Марусик 
Резюме. Двічі сліпим плацебо –  контрольованим методом досліджено вплив Нуклеїнату на гіперсприйнятли-
вість дихальних шляхів, показники фагоцитарної активності та фагоцитарного числа нейтрофілів, їх кисне-
залежного метаболізму та концентрації метаболітів монооксиду нітрогену в крові в комплексному лікуванні брон-
хіальної астми в 98 школярів. За допомогою таблиці випадкових чисел сформовані дві клінічні групи. До першої 
групи увійшли 47 осіб, які в комплексі базисної терапії приймали Нуклеїнат у дозі 0,25 г на добу протягом 21 дня. 
Другу групу сформували з 51 дитини, що отримували плацебо за тією ж схемою. Показано, що завдяки використан-
ню Нуклеїнату досягнуте зниження гіперсприйнятливості дихальних шляхів, та оптимізацію контролю захворю-
вання, на що опосередковано вказувало зростання ризику виявлення помірної сприйнятливості бронхів до гістаміну 
(СШ=3,6; 95 % ДІ: 1,3-9,3) та зниження фагоцитарної активності нейтрофілів (СШ=1,9 з 95 % ДІ (0,9-4,4)). 
Ключові слова: діти, бронхіальна астма, гіперсприйнятливість бронхів, імунітет, Нуклеїнат. 
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